Similar Papers

Paper Title
Journal
Date
Author
Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade
Alex F Herrera ... Matthew Mei
Blood | VOL. 138
Alex F Herrera, et. al.Alex F Herrera ... Matthew Mei
05 Nov 2021
Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
Alison J Moskowitz ... Craig H Moskowitz
Blood | VOL. 134
Alison J Moskowitz, et. al.Alison J Moskowitz ... Craig H Moskowitz
13 Nov 2019
Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
Steven M Horwitz ...
Blood | VOL. 138
Steven M Horwitz, et. al.Steven M Horwitz ...
05 Nov 2021
Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience
Lorenzo Falchi ...
Blood | VOL. 138
Lorenzo Falchi, et. al.Lorenzo Falchi ...
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Advances in RNA editing in hematopoiesis and associated malignancies.
Shuangshuang Pu ... Hui Cheng
Blood | VOL. -
Shuangshuang Pu, et. al.Shuangshuang Pu ... Hui Cheng
27 Jan 2025
Protection of β2GPI-Deficient Mice from Thrombosis Reflects a Defect in PAR3-facilitated Platelet Activation.
Paresh P Kulkarni ... Keith R Mccrae
Blood | VOL. -
Paresh P Kulkarni, et. al.Paresh P Kulkarni ... Keith R Mccrae
27 Jan 2025
Babesiosis and Sickle Red blood Cells: Loss of Deformability, Heightened Osmotic fragility, and Hypervesiculation.
Divya Beri ... Cheryl A Lobo
Blood | VOL. -
Divya Beri, et. al.Divya Beri ... Cheryl A Lobo
27 Jan 2025
Platelet activation and signaling in thrombus formation.
Frauke Swieringa ... Alice Assinger
Blood | VOL. -
Frauke Swieringa, et. al.Frauke Swieringa ... Alice Assinger
27 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.